KNSA

Kiniksa Pharmaceuticals International, plc KNSA

NasdaqMid CapHealthcare
InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro quality score

Rank #180 of 2,925TOP 10%

Why it scores 71Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$243.60M

Quarter to Jun 30

Net income

$25.43M

Quarter to Jun 30

Free cash flow

$46.53M

Quarter to Jun 30

Operating margin

11.2%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$2.98B total
FMR LLC
$445.82M+2.2%
Rubric Capital Management LP
$255.79M+6.7%
BAKER BROS. ADVISORS LP
$181.28M+0.3%
BlackRock, Inc.
$175.20M+462.9%
TANG CAPITAL MANAGEMENT LLC
$144.52M0.0%
VANGUARD PORTFOLIO MANAGEMENT LLC
$122.23M+8.2%
VANGUARD CAPITAL MANAGEMENT LLC
$87.03M+2.1%
MORGAN STANLEY
$64.66M+1.3%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$61.23M+7.3%
Spruce Street Capital LP
$58.71M+20.6%
DIMENSIONAL FUND ADVISORS LP
$55.94M+7.7%
Invesco Ltd.
$49.42M+2694.4%
DRIEHAUS CAPITAL MANAGEMENT LLC
$45.93M+17.5%
STATE STREET CORP
$45.03M+818.9%
ACADIAN ASSET MANAGEMENT LLC
$43.41M-49.2%
Point72 Asset Management, L.P.
$42.17M+2.9%
RICE HALL JAMES & ASSOCIATES, LLC
$39.96M+2.7%
Pictet Asset Management Holding SA
$38.92M-2.3%
GEODE CAPITAL MANAGEMENT, LLC
$38.63M+1263.2%
Jupiter Topco LLC
$37.47M--
Connor, Clark & Lunn Investment Management Ltd.
$36.62M-11.9%
D. E. Shaw & Co., Inc.
$36.44M-40.6%
TWO SIGMA INVESTMENTS, LP
$35.91M+33.4%
VICTORY CAPITAL MANAGEMENT INC
$32.29M-0.3%
SG Americas Securities, LLC
$32.23M-21.3%
See all 266 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Operating Margin

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/KNSA

Earnings Per Share

13fpro.ai/company/KNSA

Loading ratio trend…

KNSA key financials by period

Reported revenue, net income and operating margin by fiscal year, from Kiniksa Pharmaceuticals International, plc's annual filings on SEC EDGAR.

Kiniksa Pharmaceuticals International, plc reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$677.6M$59.0M11.4%
FY 2024$423.2M$-43.2M-10.8%
FY 2023$270.3M$14.1M-9.3%
FY 2022$220.2M$183.4M4.4%
FY 2021$38.5M$-157.9M—
Source: KNSA filings on SEC EDGAR →

Companies similar to KNSA

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

KNSA insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Kiniksa Pharmaceuticals International, plc (KNSA): stock profile, AI score and financials

Kiniksa Pharmaceuticals International, plc (KNSA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KNSA at 71.4/100 on a composite quality score built from its SEC filings, placing it at rank #180 of 2,925 stocks — the top 10% of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Kiniksa Pharmaceuticals International, plc reports quarterly revenue of $243.6M, net income of $25.4M, an operating margin of 11.2%. Top institutional holders of KNSA by reported 13-F value include FMR, Rubric Capital Management, BAKER BROS. ADVISORS, based on the most recent SEC filings. KNSA trades on the Nasdaq exchange and files with the SEC under CIK 1730430. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KNSA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Kiniksa Pharmaceuticals International, plc directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1730430 →